686 related articles for article (PubMed ID: 23328811)
1. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
[TBL] [Abstract][Full Text] [Related]
2. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
[TBL] [Abstract][Full Text] [Related]
3. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
6. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
8. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
9. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
10. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
14. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
[TBL] [Abstract][Full Text] [Related]
15. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
17. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
[TBL] [Abstract][Full Text] [Related]
18. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
Christians A; Hartmann C; Benner A; Meyer J; von Deimling A; Weller M; Wick W; Weiler M
PLoS One; 2012; 7(3):e33449. PubMed ID: 22428052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
